Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus- infected patients: A randomized, controlled, multicenter study

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 992-999

  Carr, Andrew ^a   Emery, Scan ^c   Lloyd, Andrew ^c   Hoy, Jennifer ^c   Garsia, Roger ^c   French, Martyn ^c   Stewart, Graeme ^c   Fyfe, Gwendolyn ^b   Cooper, David A ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b GENENTECH INC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MACROGOL; RECOMBINANT INTERLEUKIN 2;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031680651     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515653     Document Type: Article

References (19)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987;317:185-91.
2. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
3. Delta Co-Ordinating Committee. Delta: a randomised, double-blind, controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleosidc monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
5. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
6. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen production. N Engl J Med 1985;313:79-84.
7. + cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
8. Fan J, Bass HZ, Fahey JL. Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993;151:5031-40.
9. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8:757-62.
10. Ammar A, Sahraoui Y, Tsapis A, Bertoli AM, Jasmin C, Georgoulias V. Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2. J Clin Invest 1992;90:8-14.
11. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lym-phocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
12. Bonavida B, Katz J, Gottlieb M. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: 1. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL-2. J Immunol 1986;137:1157-63.
13. + T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-75.
14. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
15. Meyers FJ, Paradise C, Scudder SA, Goodman G, Konrad M. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin Pharmacol Ther 1991;49:307-13.
16. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:291-8.
17. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993;167:519-25.
18. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus infection. J Exp Med 1993;177:483-92.
19. 1 in human immunodeficiency virus type 1 infection. J Infect Dis 1996;173:1005-8.